

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A BREACH OF THE RELEVANT SECURITIES LAWS OF SUCH JURISDICTION.

THIS ANNOUNCEMENT IS FOR INFORMATION PURPOSES ONLY AND DOES NOT ITSELF CONSTITUTE A PROSPECTUS OR OFFERING MEMORANDUM OR AN OFFER FOR SALE OR SUBSCRIPTION IN RESPECT OF ANY SECURITIES IN THE COMPANY. THIS ANNOUNCEMENT DOES NOT CONSTITUTE OR CONTAIN ANY INVITATION, SOLICITATION, RECOMMENDATION, OFFER OR ADVICE TO ANY PERSON TO SUBSCRIBE FOR, OTHERWISE ACQUIRE OR DISPOSE OF ANY SECURITIES OF CRISM THERAPEUTICS CORPORATION IN ANY JURISDICTION IN WHICH ANY SUCH OFFER OR SOLICITATION WOULD BE UNLAWFUL.

THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014, AS INCORPORATED INTO UK LAW BY THE EUROPEAN UNION (WITHDRAWAL) ACT 2018 ("UK MAR"). UPON THE PUBLICATION OF THIS ANNOUNCEMENT, THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN. IN ADDITION, MARKET SOUNDINGS (AS DEFINED IN UK MAR) WERE TAKEN IN RESPECT OF CERTAIN OF THE MATTERS CONTAINED WITHIN THIS ANNOUNCEMENT, WITH THE RESULT THAT CERTAIN PERSONS BECAME AWARE OF INSIDE INFORMATION (AS DEFINED UNDER UK MAR). UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THOSE PERSONS THAT RECEIVED INSIDE INFORMATION IN A MARKET SOUNDING ARE NO LONGER IN POSSESSION OF SUCH INSIDE INFORMATION, WHICH IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.

15 December 2025



CRISM Therapeutics Corporation
("CRISM", "CRISM Therapeutics" or the "Company")

Result of Retail Offer

Further to the announcement by the Company in respect of the Retail Offer dated 10 December 2025, CRISM Therapeutics Corporation announces that, following the closing of the Retail Offer on the BookBuild platform today at 12.00 p.m., the Company has raised gross proceeds of £59,610 (the "**Retail Offer**") by way of a subscription of 662,332 Retail Offer Shares at the Issue Price of 9 pence per share.

The proceeds of the Retail Offer together with the Placing announced on 10 December 2025 (together the "**Proceeds**"), will enable the Company to progress its MHRA approved, Phase 2 open-label clinical trial of irinotecan-ChemoSeed in patients with surgically resectable glioblastoma, with first patients expected to be dosed in Q1 2026.

Admission and Total Voting Rights

Application has been made to the London Stock Exchange for admission of the Retail Offer Shares ("**Admission**"). It is expected that Admission will become effective and that trading will commence in the Placing Shares at 8.00 a.m. on or around 16 December 2025, or such later date as may be agreed between the Company and SP Angel. The Retail Offer Shares will rank *pari passu* with the Company's existing ordinary shares.

Following the issue of the Retail Offer Shares, the total issued share capital of the Company will consist of 51,735,266 ordinary shares. The Company does not hold any ordinary shares in treasury. Therefore, the total number of voting rights in the Company is 51,735,266 and this figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.

Other than where defined, capitalised terms used in this Announcement have the meanings given to them in the announcements of 10 December 2025.

-Ends-

Enquiries:

Company
CRISM Therapeutics

Nomad and Broker
S P Angel Corporate

Financial PR
Bursen Buchanan

CRISM Therapeutics Corporation	CRISM Therapeutics Finance LLP	Burson Buchanan
Andrew Webb, Exec. Chair	Richard Morrison (Corp Fin)	Mark Court / Jamie Hooper
Chris McConville, CSO	Adam Cowl (Corp Fin)	CRISM@buchanancomms.co.uk
	Vadim Alexandre (Sales)	
	Rob Rees (Sales)	
via Burson Buchanan	+44 (0) 20 3470 0470	+44 (0) 20 7466 5000

About CRISM Therapeutics Corporation

CRISM Therapeutics Corporation has developed an innovative drug delivery technology to improve the clinical performance of cancer treatments for solid tumours through the local delivery of chemotherapy drugs.

ChemoSeed, CRISM's lead product, can be implanted directly into the tumour or the resection margin following the removal of a tumour. This directs that therapeutic concentrations of chemotherapy drugs reach the deep-seated tumour tissue or cover the entire resection margin. In the case of treating glioblastoma, ChemoSeeds can be implanted during surgery thereby bypassing the blood brain barrier, which prevents other treatments from being able to reach the tumour and be effective.

CRISM will initiate its registration-grade Phase 2 clinical trial of irinotecan-ChemoSeed™ in patients with surgically resectable glioblastoma in Q1 2026.

For more information please visit: <https://www.crismltherapeutics.com/>

The Company's LEI is 213800XFW6MKV/CHHPW88.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

ROITABITMTTBIA